Endocrine Abstracts

A wealth of evidence has substantiated GLP-1’s role in regulating appetite and energy intake in humans. Meta-analyses confirm that i.v. infusion of native GLP-1 reduces energy intake in lean and overweight subjects1. A high-protein diet is known to increase satiety and this effect appears to be at least partly mediated by GLP-1. Increased post-prandial GLP-1 levels have been measured in healthy subjects following high-protein meals compared with medium- and low...

In 1996, we showed that GLP-1 is a satiety hormone in humans, and increased post-prandial GLP-1 levels following high protein meals have shown to be at least partially responsible for the high satiating effect of protein. The natural ligands to stimulate GLP-1 release seem to be peptide fragments and monoacylglycerides.The once-daily GLP-1 analogue liraglutide at doses up to 3.0 mg was compared with placebo or orlistat over 104 weeks as adjunct to diet a...

Background: Familial resemblance was shown for body composition and risk factors in several studies. In twin studies which are powerful tool to assess genetically mediated traits significant resemblance was found in twins reared apart. In pairs of monozygotic twins was found significant resemblance in response to positive and negative energy balance. Aim of the study was to evaluate relationship of anthropometric parameters of parents and socioeconomic characteristics of famil...

Objectives: Measurement of TSH-receptor antibodies (TRAb) in hyperthyroid, pregnant women is an important tool when distinguishing between the autoimmune Graves’ disease and the physiological gestational hyperthyroidism. Evidence to support a cut-off for TRAb in early pregnancy is needed along with information on the frequency and follow-up of TRAb-positive as opposed to TRAb-negative hyperthyroidism.Methods: Within the North Denmark Region Pregnanc...

Aims/objectives: Obesity and prediabetes are risk factors for developing T2D. 5–10% weight-loss can reduce risk of developing T2D by >50%. The 3-year part of this phase 3 trial investigated effects of liraglutide 3.0 mg, as adjunct to diet+exercise, in delaying onset of T2D over 3 years, body-weight and cardiometabolic risk factors in adults with obesity or overweight with comorbidities, and diagnosed with prediabetes at screening.Methods: Indiv...

Objective: Physiological alterations challenge the assessment of maternal thyroid function in pregnancy. It remains uncertain how the reference ranges vary by week of pregnancy, and how the classification of maternal thyroid disease vary by analytical method and type of thyroid function test.Method: Consecutively collectedserum samples from 6.282 pregnant women in the North Denmark Region, 2011–2013, were used for the measurement of thyrotropin (TS...

11beta-hydroxysteroid dehydrogenase regulates glucocorticoid action, by interconverting cortisone (E) to cortisol (F). The Type 1 isozyme (11betaHSD1) is an oxoreductase expressed in adipose tissue, where it may play a role in the pathogenesis of visceral obesity.We have characterised two polymorphic (CA)n microsatellite markers within intron 4 of the HSD11B1 gene, termed (CA)15 and (CA)19. In an earlier study evaluating a 'normal' population (MONICA co...

Objective: Hypothalamic obesity results in severe weight-gain and increased risk of cardiovascular and metabolic mortality. We aimed to assess the safety and efficacy of Tesomet (tesofensine plus metoprolol), and ongoing requirements in pituitary hormone replacement adjustments in adults with acquired hypothalamic obesity, a rare disease with no approved therapyResearch design, patients and methodsTwenty-one adults with hypothalami...

Background: The 3-year part of this trial investigated the effect of liraglutide 3.0 mg, as an adjunct to diet+exercise, in delaying onset of T2D (primary endpoint) in adults with prediabetes and obesity (BMI ≥30 kg/m2) or overweight (≥27 kg/m2) with comorbidities.Methods: Participants were randomised 2:1 to once-daily subcutaneous liraglutide 3.0 mg or placebo plus 500 kcal/day deficit diet and 150...

Background and objective: Hypothalamic obesity is characterized by rapid and severe weight-gain with increased risk of cardiovascular and metabolic disorders. Currently, there are no approved or effective pharmacological treatments and conventional weight management remain largely ineffective in hypothalamic obesity. This trial investigated safety and efficacy of Tesomet (0.5 mg tesofensine and 50 mg metoprolol) in hypopituitary patients with hypothalamic obesity.<p class=...